Korro Bio Secures $85M Oversubscribed PIPE, Extends Runway to H2 2028
Korro Bio raised gross proceeds of $85 million through an oversubscribed PIPE, selling 4.5 million shares at $11.11 and pre-funded warrants for 3.15 million shares at $11.109. Combined with $85.2 million cash, funds extend its financial runway into H2 2028 supporting KRRO-121 and AATD program clinical data and longevity research.
1. Financing Overview
Korro Bio has entered into an oversubscribed private investment in public equity financing expected to yield approximately $85 million in gross proceeds, with a closing date set for March 10, 2026, subject to customary conditions.
2. Share and Warrant Structure
Under the subscription agreement, Korro is selling 4,501,928 common shares at $11.11 each and pre-funded warrants exercisable at $0.001 with a $11.109 purchase price for 3,148,836 shares.
3. Runway Extension and Corporate Plans
Combined with $85.2 million in cash, cash equivalents and marketable securities as of December 31, 2025, the proceeds will extend Korro’s operational runway into the second half of 2028, with remaining funds allocated to working capital and general corporate purposes.
4. Pipeline Program Funding
The financing supports clinical data readouts for KRRO-121 in urea cycle disorders, Korro’s GalNAc-conjugated AATD oligonucleotide program, and advancement of its longevity and liver health AMPKγ1 pathway program.